Welcome to
CIS BIOPHARMA.
Cancer Therapies.
Precision Oncology
We pioneer precision cancer therapies that selectively target tumor cells. Our next-generation antibody-drug conjugates and radioligand therapies are designed to improve the quality of life for cancer patients worldwide.
Advancing cancer research
Driving Progress
in Cancer Therapy
Our purpose is to push the boundaries of cancer therapy, and offer cancer patients longer and better lives.
Christoph Schäfer, Co-founder, CEO
Pipeline of
Precision Therapies
By harnessing the power of monoclonal antibodies and nanobodies we are developing highly specific therapies that bind to structures on the tumor cell surface.
CIS BIOPHARMA's therapies target antigens that are highly overexpressed on cancer cells while maintaining minimal expression in healthy tissues.
The targeted antigens are found over a wide board of cancer indications, including lung, brain, breast, colorectal, ovarian and other types of cancer.
CBO-001 targeting
lung cancer, SCLC
Our lead program is designed to offer new hope for cancer patients facing incurable lung cancer, specifically a very aggressive form known as small cell lung cancer, SCLC.
Pipeline Pipeline
CBO-002 targeting
brain metastases, BM
CBO-002 is specifically designed to overcome the challenges of treating brain metastases, originating from primary tumors in the lung, breast, or gastrointestinal tract.
CBO-003 targeting
glioblastoma, GBM
Glioblastoma multiforme, GBM, is a tumor that originates in the brain. Our technology is designed to overcome the defense mechanisms of this aggressive brain tumor.
Pipeline Pipeline
Platform of biologics, linkers and payloads
Our discovery platform includes the expertise and the infrastructure to develop proprietary targeting moieties comprising a variety of linker/drug combinations, both validated as well as proprietary.
For patients facing poor prognosis
Addressing Cancer
with High Unmet Need
We are dedicated to developing novel therapies addressing high unmet medical needs in oncology. Our pipeline products target cancers with limited treatment options and aim to improve patient outcomes. Our focus is on aggressive diseases such as lung cancer and brain tumors.
Our focus
Lung and Brain TUMORS
Small cell lung cancer, SCLC, brain tumors, BT, and brain metastases, BM, are devastating diseases. Patients often face a grim prognosis, and standard of care significantly impacts cognitive function and quality of life.
SCLC patients do not live
5 years after diagnosis
5 years after diagnosis
0
%
SCLC patients face
relapse after chemotherapy
relapse after chemotherapy
0
%
patients with brain metastases
pass away within 6 months
pass away within 6 months
0
%
AREAS OF INNOVATION
Targeted Therapies
CIS BIOPHARMA's innovative therapeutic modalities leverage high-affinity antibodies and nanobodies to selectively deliver cytotoxic payloads to cancer cells, thereby minimizing damage to non-malignant tissues.
Our approach is based on the differential expression of tumor-associated antigens, CD 171 and CD 276, to achieve targeted drug delivery with enhanced specificity.
This strategy shows particular promise in addressing malignancies with historically poor prognoses and limited therapeutic options, such as small cell lung cancer, SCLC, glioblastoma multiforme, GBM, and metastatic brain lesions, BM.
Platform
At CIS BIOPHARMA we have established a cutting-edge bioconjugation platform, leveraging state-of-the-art infrastructure and expertise in chemistry, protein engineering, and pharmaceutical sciences.
Our focus is on developing innovative oncological therapeutics, particularly antibody-drug conjugates, ADCs, and other targeted therapies. We employ both validated and novel drug/linker technologies to create precision therapies with high tumor specificity.
Our platform and skills position CIS BIOPHARMA at the forefront of next-generation cancer therapy development.
ADCs are targeted cancer therapies composed of three components: a monoclonal antibody, a linker, and a cytotoxic drug. The antibody targets specifically cancer cells, the cytotoxic drug kills the tumor cell, and the linker connects both while in circulation. Upon tumor localization, the linker is cleaved, activating the drug within the tumor cells.
ADCs offer a targeted cancer treatment by selectively attacking tumor cells, minimizing damage to healthy tissues and reducing systemic toxicity. Traditional chemotherapy induces non-specific damage to healthy cells alongside cancer cells, and is therefore limited in dosing and efficacy against tumors.
RLTs are targeted cancer treatments composed of two components: a targeting ligand and a radioisotope. The ligand binds to specific cancer cell markers, delivering the radioisotope to these cells. The radioisotope emits radiation to destroy the cancer cells, minimizing damage to surrounding healthy tissue."
RLT and traditional radiation therapy both harness the power of radiation to combat cancer, yet they employ distinct mode of actions. Traditional radiation therapy uses external beams aimed at the tumor, impacting both cancerous and nearby healthy tissues. In contrast, RLT administers a radioactive drug intravenously, with ligands guiding radioisotopes directly to specific cancer cells, ensuring targeted treatment.
